- Policy
- Multiple low-dose Kerendia Rx subject to reimb cuts
- by Lee, Tak-Sun Feb 20, 2024 06:00am
- Kerendia Tab, a new drug for chronic kidney disease with diabetes mellitus that was reimbursed in February this year, was added to the list of low-content multiple-dose prescription reimbursement cuts. As the price for the high and low-dose formulations were set the same for the drug, there is virtually no incentive to prescribe multipl
- Policy
- Hanmi launches Zytiga generic combo after first generic
- by Lee, Tak-Sun Feb 16, 2024 06:00am
- Hanmi Pharmaceutical, which attracted wide attention by launching the first generic version of the prostate cancer treatment Zytiga last year, set out to target the market again by quickly developing a combination drug. On the 14th, the Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's Abiteron Duo Tab 500/2.5mg. The
- Policy
- MFDS will inspect growth hormones and cold chains this year
- by Lee, Hye-Kyung Feb 16, 2024 05:59am
- The Ministry of Food and Drug Safety has included 'medical institutions and pharmacies handling growth hormone drugs' and 'cold chain compliance of high-risk items such as vaccines' in this year's planned inspections. The ' Biopharmaceuticals and Herbal Medicine Bureau’s Basic Plan for Manufacturing and Distribution Management in 2024,' whic
- Policy
- ‘Trelegy 200 Ellipta’ concludes negotiations with the NHIS
- by Lee, Tak-Sun Feb 15, 2024 05:59am
- ‘Trelegy 200 Ellipta Inhaler,’ a triple combination therapy for COPD, has completed the negotiations with the National Health Insurance Service (NHIS). The drug is expected to be listed for health insurance reimbursement soon. According to industry experts on the 13th, ‘Trelegy 200 Ellipta Inhaler,’ a COPD triple combination therap
- Policy
- The guidelines for PVA will be revised soon
- by Lee, Tak-Sun Feb 15, 2024 05:58am
- The National Health Insurance Service (NHIS) is likely to seek opinions from the pharmaceutical industry soon to revise the operational guidelines on the price-volume agreement (PVA) program. The revised guidelines draw attention as they include an agenda for easing on products that have reduced their prices more than three times in fiv
- Policy
- Price cut hold for Forxiga, Xigduo, Atmeg Combi are extended
- by Lee, Jeong-Hwan Feb 14, 2024 05:40am
- The administrative stay of execution of the price reduction disposition for AstraZeneca's diabetes drugs Forxiga (dapagliflozin), Xigduo (dapagliflozin+metformin), and Korea United Pharm’s Atmeg Combigel (atorvastatin 10 mg + omega 3) has been extended, and the insurance ceiling price for the drugs will remain unchanged until June 30.
- Policy
- Chinese MM drug Xpovio reattempts reimb listing in KOR
- by Lee, Tak-Sun Feb 14, 2024 05:40am
- A new drug for multiple myeloma that was developed by the Chinese pharmaceutical company Antengene is attempting reimbursement listing again in Korea. The drug’s name is Xpovio Tab 20mg (Selinexor). The drug received a non-reimbursement decision at the Drug Reimbursement Evaluation Committee meeting that was held in November last year.
- Policy
- Will Enhertu·Ilaris·morning sickness drugs be reimbursed
- by Lee, Tak-Sun Feb 14, 2024 05:40am
- Whether Enhertu Inj 100mg, Ilaris Injection Sol, and the morning sickness drugs that had passed the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee review on the 1st, will be listed for reimbursement in April is gaining attention. As all three drugs are highly sought-after by patients and the pub
- Policy
- HIRA to revise guidelines on new drugs utility assessment
- by Lee, Tak-Sun Feb 13, 2024 05:52am
- The Health Insurance Review and Assessment Service (HIRA) will revise the guidelines on indirect comparison for assessing the clinical utility of new drugs. For this purpose, HIRA is currently recruiting researchers for contract research work. On the 1st, the HIRA initiated public bidding for ‘Research services to revise guidelines on
- Policy
- Ulcerative colitis drug Omvoh is approved in Korea
- by Lee, Hye-Kyung Feb 13, 2024 05:51am
- The Ministry of Food and Drug Safety (MFDS, Minister: Yu-Kyoung Oh) announced that it has approved Lilly Korea's new drug Omvoh Inj (mirikizumab-mrkz, recombinant) for the treatment of ulcerative colitis on the 7th. Omvoh Inj. 20 mg/ml is a monoclonal antibody drug that binds to the p19 subunit of interleukin (IL)-23, providing a new th
